HomeCompareDCHPF vs EQR

DCHPF vs EQR: Dividend Comparison 2026

DCHPF yields 1.17% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DCHPF wins by $7.85M in total portfolio value· pulled ahead in Year 4
10 years
DCHPF
DCHPF
● Live price
1.17%
Share price
$46.90
Annual div
$0.55
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.89M
Annual income
$6,778,497.55
Full DCHPF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — DCHPF vs EQR

📍 DCHPF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCHPFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCHPF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCHPF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCHPF
Annual income on $10K today (after 15% tax)
$99.68/yr
After 10yr DRIP, annual income (after tax)
$5,761,722.92/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, DCHPF beats the other by $5,758,476.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCHPF + EQR for your $10,000?

DCHPF: 50%EQR: 50%
100% EQR50/50100% DCHPF
Portfolio after 10yr
$3.96M
Annual income
$3,391,158.58/yr
Blended yield
85.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

DCHPF
No analyst data
Altman Z
4.3
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCHPF buys
0
EQR buys
0
No recent congressional trades found for DCHPF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCHPFEQR
Forward yield1.17%4.73%
Annual dividend / share$0.55$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%15.8%
Portfolio after 10y$7.89M$40.5K
Annual income after 10y$6,778,497.55$3,819.61
Total dividends collected$7.78M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: DCHPF vs EQR ($10,000, DRIP)

YearDCHPF PortfolioDCHPF Income/yrEQR PortfolioEQR Income/yrGap
1$10,935$234.54$11,248$547.57$313.00EQR
2$12,179$479.37$12,701$666.53$522.00EQR
3$14,030$998.01$14,405$814.59$375.00EQR
4← crossover$17,161$2,148.88$16,413$999.84+$748.00DCHPF
5$23,275$4,912.97$18,795$1,232.92+$4.5KDCHPF
6$37,359$12,454.96$21,639$1,527.95+$15.7KDCHPF
7$77,342$37,367.67$25,057$1,903.80+$52.3KDCHPF
8$227,353$144,597.06$29,197$2,385.87+$198.2KDCHPF
9$1,037,762$794,493.85$34,250$3,008.70+$1.00MDCHPF
10$7,888,903$6,778,497.55$40,467$3,819.61+$7.85MDCHPF

DCHPF vs EQR: Complete Analysis 2026

DCHPFStock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Full DCHPF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this DCHPF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCHPF vs SCHDDCHPF vs JEPIDCHPF vs ODCHPF vs KODCHPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.